Home Alzheimer’s Disease Quoc-Dien Trinh, MD, on Declines in Cancer & Precancer Diagnoses During COVID-19...

Quoc-Dien Trinh, MD, on Declines in Cancer & Precancer Diagnoses During COVID-19 Pandemic

The urologist at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center spoke about the impact of a decline in cancer screening tests being performed during the first wave of the pandemic.

Findings from investigators at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center published in JAMA Oncology suggested a significant decline in cancer and precancer diagnoses within the health care system during the first peak of the coronavirus disease 2019 (COVID-19) pandemic due to a drop in the number of cancer screening tests being performed.1

Though the current study focused on a single, large health care system in one part of the country, emerging data suggest these findings have relevance for other regions as well.

“This investigation is especially timely given that we are currently dealing with a second, and potentially worse wave of the pandemic,” co-senior author…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments